Biomarkers in melanoma: predisposition, screening and diagnosis

References

• Rigel DS, Carucci JA. Malignant melanoma: prevention, early detection and treatment in the 21st century. CA Cancer Clin. 50(4), 215–236; quiz 237–240 (2000).
   Google Scholar
• Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1999. CA Cancer 1 Clin. 49(1), 8–31 (1999).
   Google Scholar
• Diepgen TL, Mahler V The epidemiology of skin cancer. BE j Dermatol 146\(Suppl. 61), 1–6 (2002).
   Google Scholar
• Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer83(1), 18–29 (1999).
   Google Scholar
• Lipsker DM, Hedelin G, Heid E, Grosshans EM, Cribier BJ. Striking increase of thin melanomas contrasts with stable incidence of thick melanomas. Arch. Dennatol 135(12), 1451–1456 (1999).
   Google Scholar
• MacLennan R, Green AC, McLeod GR, Martin NG. Increasing incidence of cutaneous melanoma in Queensland, Australia. J. Natl Cancer Inst. 84(18), 1427–1432 (1992).
   PubMedGoogle Scholar
• Hiatt RA, Fireman B. The possible effect of increased surveillance on the incidence of malignant melanoma. Rev. Med. 15(6), 652–660 (1986).
   Google Scholar
• Dennis LK. Analysis of the melanoma epidemic, both apparent and real: data from the 1973 through 1994 surveillance, epidemiology and end results program registry. Arch. Dermatol 135(3), 275–280 (1999).
   Google Scholar
• Richard MA, Grob JJ, Avril MF eta]. Melanoma and tumor thickness: challenges of early diagnosis. Arch. Dermatol 135 (3), 269–274 (1999).
   Google Scholar
• MacKie R, Bray C, Hole D etal. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 360 (9333), 587 (2002).
   PubMed Web of Science ®Google Scholar
• •Demonstrates an increase in survival for younger individuals and overall decrease in mortality for women. These trends are attributed to both primary and secondary preventive efforts. iiCrowley NJ, Dodge R, Vollmer RT, Seigler HE Malignant melanoma in black Americans. A trend toward improved survival. Atrh. Sing 126(11), 1359–1364; discussion 1365 (1991).
   Google Scholar
• Richard MA, Grob JJ, Avril MF eta]. Delays in diagnosis and melanoma prognosis (I): the role of patients. Int. J. Cancer89(3), 271–279 (2000).
   Google Scholar
• •Attributes delays in diagnosis to lack of knowledge and stresses the importance of public education, particularly for high-risk groups, such as elderly men. Suggest some melanomas will still continue to escape these efforts due to rapid growth.
   Google Scholar
• Richard MA, Grob JJ, Avril MF eta]. Delays in diagnosis and melanoma prognosis (II): the role of doctors. Int. J. Cancer89(3), 280–285 (2000).
   Google Scholar
• •Dermatologists most accurate in melanoma detection. Suggest that systematic skin examination and improved physician training could improve melanoma detection.
   Google Scholar
• Epstein DS, Lange JR, Gruber SB, Mond M, Koch SE. Is physician detection associated with thinner melanomas? JAIVIA 281(7), 640–643 (1999).
   Google Scholar
• Gilchrest BA, Eller MS, Geller AC, Yaar M. The pathogenesis of melanoma induced by ultraviolet radiation. N bkzglj Med. 340(17), 1341–1348 (1999).
   Google Scholar
• Autier P, Dore JE Influence of sun exposure during childhood and during adulthood on melanoma risk. Int. j Cancer 77,533–537 (1998).
   PubMed Web of Science ®Google Scholar
• •Study of the relative contributions of childhood and adult sun exposure finding that childhood sun exposure is a significant risk-factor for melanoma compared with adult sun exposure.
   Google Scholar
• Walter SD, King ND, Marrett LD. Association of cutaneous malignant melanoma with intermittent exposure to ultraviolet radiation: results of case-control study in Ontario, Canada. Int. j Epidemiol 28, 418–427 (1999).
   Google Scholar
• Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control 12(1), 69–82 (2001).
   PubMed Web of Science ®Google Scholar
• ••Good overview of sun exposure andmelanoma risk. Exposure to high levels of sunlight in childhood is a strong determinant of melanoma risk but sun exposure in adulthood also plays a role.
   Google Scholar
• Tucker MA, Halpern A, Holly EA eta]. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAIVIA 277(18), 1439–1444 (1997).
   Google Scholar
• Greene MET. The genetics of hereditary melanoma and nevi. 1998 update. Cancer 86(11 Suppl.), 2464–2477 (1999).
   Google Scholar
• ••Excellent review on hereditary melanoma.
   Google Scholar
• Berwick M, Halpern A. Melanoma epidemiology. CUI7: Opin. Oncol 9(2), 178–182 (1997).
   Google Scholar
• Bataille V, Bishop JA, Sasieni P etal Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Brj Cancer 73(12), 1605–1611 (1996).
   PubMed Web of Science ®Google Scholar
• Whiteman DC, Parsons PG, Green AC. p53 expression and risk factors for cutaneous melanoma: a case-control study. Int.j Cancer 77 (6), 843–848 (1998).
   Google Scholar
• Ragnarsson-Olding BK, Karsberg S, Platz A, Ringborg UK. Mutations in the TP53 gene in human malignant melanomas derived from sun-exposed skin and unexposed mucosal membranes. Melanoma Res. 12(5), 453–463 (2002).
   Google Scholar
• ••Similar frequency of p5..? C to T mutationsat dypyrimidine sites (signature mutation for UV light) in sun protected, mucosal sites indicating that other factors play a role in induction of mutations in melanoma.
   Google Scholar
• Geller AC, Sober AJ, Zhang Z eta]. Strategies for improving melanoma education and screening for men age 50 years of age or older: findings from the American Academy of Dermatological National Skin Cancer Screening Program. Cancer95(7), 1554–1561 (2002).
   Google Scholar
• •Demonstrated a higher predictive value for melanoma screening in men above 50 years of age with a history of changing mole or skin types land 11 compared with all others.
   Google Scholar
• Gibbs P, Brady BM, Robinson WA. The genes and genetics of malignant melanoma. Cutan Med. Surg. 6(3), 229–235 (2002).
   Google Scholar
• Zhu G, Duffy DL, Eldridge A et al A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: a maximum-likelihood combined linkage and association analysis in twins and their sibs. Am. j Hum. Genet. 65(2), 483–492 (1999).
   Google Scholar
• Healy E, Flannagan N, Ray A etal Melanocortin-l-receptor gene and sun sensitivity in individuals without red hair. Lancet 355(9209), 1072–1073 (2000).
   PubMedGoogle Scholar
• •Implicates MC1R in sun-sensitivity and discuss gene—environmental interaction.
   Google Scholar
• McGregor B, Pfitzner J, Zhu G etal Genetic and environmental contributions to size, color, shape and other characteristics of melanocytic naevi in a sample of adolescent twins. Genet. Epidemiol 16(1), 40–53 (1999).
   PubMedGoogle Scholar
• Halpern AC, Altman JE Genetic predisposition to skin cancer. CUI7: Opin. Oncol 11(2), 132–138 (1999).
   Google Scholar
• Siskind V, Aitken J, Green A, Martin N. Sun exposure and interaction with family history in risk of melanoma, Queensland, Australia. hit.j Cancer 97 (1), 90–95 (2002).
   Google Scholar
• •Demonstrates that sun exposure in childhood and in adulthood are important determinants of melanoma but not in those rare families with high melanoma susceptibility where genetic factors appear more important.
   Google Scholar
• Goldstein AM, Fraser MC, Struewing JP etal Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N big/f Med. 333(15), 970–974 (1995).
   Google Scholar
• Lynch HT, Brand RE, Hogg D et al Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families, the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 94(1), 84–96 (2002).
   Google Scholar
• Borg A, Sandberg T, Nilsson K etal High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. Natl Cancer Inst. 92 (15), 1260–1266 (2000).
   Google Scholar
• Holland EA, Schmid H, Kefford RF, Mann GJ. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosomes Cancer25 (4), 339–348 (1999).
   Google Scholar
• Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N big/f Med. 333(15), 975–977 (1995).
   Google Scholar
• Bressac-de-Paillerets B, Avril ME, Chompret A, Demenais E Genetic and environmental factors in cutaneous malignant melanoma. Biochimie 84(1), 67–74 (2002).
   PubMedGoogle Scholar
• Goldstein AM, Tucker MA. Genetic epidemiology of cutaneous melanoma: a global perspective. Arch. Dermatol 137(11), 1493–1496 (2001).
   PubMedGoogle Scholar
• Sturm RA. Skin colour and skin cancer — MC1R, the genetic link. Melanoma Res. 12(5), 405–416 (2002).
   Google Scholar
• ••Most recent review of the importance ofthe melanocortin-1 receptor gene to melanoma's pathogenesis. Suggest that genetic and chemical assessment of melanin synthesis rather than skin color will be the best indicator for skin cancer risk.
   Google Scholar
• Castellano M, Parmiani G. Genes involved in melanoma: an overview of INK4a and other loci. Melanoma Res. 9(5), 421–432 (1999).
   Google Scholar
• Davies H, Bignell GR, Cox C etal Mutations of the BRAF gene in human cancer. Nature 417(6892), 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Feng Y, Shi J, Goldstein AM, Tucker MA, Nelson MA. Analysis of mutations and identification of several polymorphisms in the putative promoter region of the P34CDC2-related CDC2Llgene located at 1P36 in melanoma cell lines and melanoma families. Int.j Cancer 99 (6), 834–838 (2002).
   Google Scholar
• Liu L, Goldstein AM, Tucker MA etal Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or pl9ARE Genes Chromosomes Cancer 19(1), 52–54 (1997).
   Google Scholar
• Platz A, Hansson J, Mansson-Brahme E etal Screening of germline mutations in the CDKN24 and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. Natl Cancer Inst. 89(10), 697–702 (1997).
   Google Scholar
• Platz A, Hansson J, Ringborg U. Screening of germline mutations in the CDK4, CDK72C and TP53genes in familial melanoma: a clinic-based population study. hit.j Cancer78(1), 13–15 (1998).
   Google Scholar
• Newton Bishop JA, Harland M, Bennett DC etal Mutation testing in melanoma families: INK4A, CDK4 and INK4D BE Cancer80(1–2), 295–300 (1999).
   Google Scholar
• Shennan MG, Badin AC, Walsh S etal Lack of germline CDK6 mutations in familial melanoma. Oncogene 19(14), 1849–1852 (2000).
   Google Scholar
• Kennedy C, Naipal A, Gruis NA etal. MICA gene polymorphism is not associated with an increased risk for skin cancer. .1. Invest. Dermatol 118(4), 686–691 (2002).
   Google Scholar
• Kumar R, Smeds J, Berggren P etal. A single nucleotide polymorphism in the 3' untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare. Int.j Cancer 95(6), 388–393 (2001).
   Google Scholar
• Deichmann M, Mollenhauer J, Helmke B etal Analysis of losses of heterozygosity of the candidate tumour suppressor gene DMBT1 in melanoma resection specimens. Oncology 63 (2), 166–172 (2002) .
   Google Scholar
• Boni R, Vortmeyer AO, Huang S, Burg G, Hofbauer G, Zhuang Z. Mutation analysis of the MEN1 tumour suppressor gene in malignant melanoma. Melanoma Res. 9(3), 249–252 (1999).
   Google Scholar
• Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. Disruption of the MIVIACII PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57(17), 3660–3663 (1997).
   Google Scholar
• Ciotti P, Struewing JP, Mantelli M eta]. A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. Ainj Hum. Genet. 67(2), 311–319 (2000).
   Google Scholar
• •Demonstrates the presence of a founder mutation in a defined geographic area, which may provide an opportunity to study disease penetrance and the effect of environmental factors on the background of a common genetic susceptibility.
   Google Scholar
• Pollock PM, Spurr N, Bishop T etal Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum. Mutat. 11(6), 424–431 (1998).
   Google Scholar
• Box NF, Duffy DL, Chen W et al MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am.j Hum. Genet. 69(4), 765–773 (2001).
   Google Scholar
• van der Velden PA, Sandkuijl LA, Bergman W etal Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am. j Hum. Genet. 69(4), 774–779 (2001).
   Google Scholar
• Aitken JF, Bailey-Wilson J, Green AC, MacLennan R, Martin NG. Segregation analysis of cutaneous melanoma in Queensland. Genet. Epiclemiol 15(4), 391–401 (1998).
   PubMedGoogle Scholar
• •Highlights the genetic heterogeneity in melanoma inheritance and suggest that other familial factors, such as pigmentation, skin type and sun exposure habits, play an important role in the familial clustering of melanoma.
   Google Scholar
• Bishop DT, Demenais F, Goldstein etal Geographical variation in the penetrance of CDKN2A mutations for melanoma. j Natl Cancer Inst. 94(12), 894–903 (2002).
   Google Scholar
• ••Demonstrates that the penetrance varieswith melanoma population incidence rates, signifying that the same factors that affect population incidence of melanoma may also mediate CDKN2A penetrance.
   Google Scholar
• Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. j Clin. Oncol 17(10), 3245–3251 (1999).
   Google Scholar
• Tucker MA, Fraser MC, Goldstein AM etal A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families. Cancer94(12), 3192–3209 (2002).
   PubMedGoogle Scholar
• ••Excellent documentation of the lives ofdysplastic nevi revealing that they are markers of risk for, not precursors of, melanoma.
   Google Scholar
• Rebbeck TR, Kanetsky PA, Walker AH etal P gene as an inherited biomarker of human eye color. Cancer Epiclemiol Biomarkers Bev 11(8), 782–784 (2002).
   PubMedGoogle Scholar
• Tomescu D, Kavanagh G, Ha T, Campbell H, Melton DW. Nucleotide excision repair gene XPD polymorphisms and genetic predisposition to melanoma. Carcinogenesis 22(3), 403–408 (2001).
   PubMedGoogle Scholar
• Winsey SL, Haldar NA, Marsh HP etal A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res. 60(20), 5612–5616 (2000).
   Google Scholar
• Shahbazi M, Pravica V, Nasreen N et al Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359(9304), 397–401 (2002).
   PubMed Web of Science ®Google Scholar
• Osborne JE, Hutchinson PE. Vitamin D and systemic cancer: is this relevant to malignant melanoma? BE j Dermatol 147(2), 197–213 (2002).
   Google Scholar
• Hutchinson PE, Osborne JE, Lear JT etal Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin. Cancer Res. 6(2), 498–504 (2000).
   PubMedGoogle Scholar
• Lafuente A, Molina R, Palou J, Castel T, Moral A, Trias M. Phenotype of glutathione 5-transferase Mu (GSTM1) and susceptibility to malignant melanoma. MMM group. Multidisciplinary Malignant Melanoma Group. BE j Cancer 72 (2), 324–326 (1995).
   Google Scholar
• Strange RC, Ellison T, Ichii-Jones F etal Cytochrome P450 CYP2D6 genotypes: association with hair colour, Breslow thickness and melanocyte stimulating hormone receptor alleles in patients with malignant melanoma. Pharmacogenetics 9(3), 269–726 (1999).
   Google Scholar
• Edman RL, Klaus SN. Is routine screening for melanoma a benign practice? JAIVIA 284(7), 883–886 (2000).
   Google Scholar
• Helfand M, Mahon SM, Eden KB, Frame PS, Orleans CT Screening for skin cancer. A117. I Prev. Med. 20(3 Suppl.), 47–58 (2001).
   Google Scholar
• ••Excellent review of all published studies onskin cancer screening. Suggests that skin cancer screening, perhaps using a risk-assessment technique to identify high-risk patients who are seeing a physician for other reasons, merits additional study as a strategy to address the excess burden of disease in older adults.
   Google Scholar
• Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol 3(3), 159–165 (2002).
   PubMed Web of Science ®Google Scholar
• •Good review of dermoscopy and suggest that it is a useful tool only in the hands of an experienced clinician.
   Google Scholar
• Wolf IH, Smolle J, Soyer HP, Kerl H. Sensitivity in the clinical diagnosis of malignant melanoma. Melanoma Res. 8(5), 425–429 (1998).
   Google Scholar
• Grin CM, Kopf AW, Welkovich B, Bart RS, Levenstein MJ. Accuracy in the clinical diagnosis of malignant melanoma. Arch. Dermatol 126(6), 763–766 (1990).
   Google Scholar
• Chen SC, Bravata DM, Weil E, Olkin I. A comparison of dermatologists' and primary care physicians' accuracy in diagnosing melanoma: a systematic review. Arch. Dermatol 137(12), 1627–1634 (2001).
   PubMedGoogle Scholar
• Koh HK, Norton LA, Geller AC et al Evaluation of the American Academy of Dermatology's National Skin Cancer Early Detection and Screening Program. Am. Acad. Dermatol 34(6), 971–978 (1996).
   Google Scholar
• Oliveria S, Dusza S, Berwick M. Issues in the epidemiology of melanoma. Expert Rev Anticancer Ther. 1(3), 453–459 (2001).
   PubMedGoogle Scholar
• Brenner S, Tamir E. Early detection of melanoma: the best strategy for a favorable prognosis. Clin. Dermatol 20(3), 203–211 (2002).
   PubMedGoogle Scholar
• Landau M, Matz H, Tur E, Dvir M, Brenner S. Computerized system to enhance the clinical diagnosis of pigmented cutaneous malignancies. int. j Dermatol 38(6), 443–446 (1999).
   Google Scholar
• Marchesini R, Bono A, Bartoli C, Lualdi M, Tomatis S, Cascinelli N. Optical imaging and automated melanoma detection: questions and answers. Melanoma Res. 12(3), 279–286 (2002).
   Google Scholar
• •Most current review of technologic aids and their performance in the detection of melanoma.
   Google Scholar
• Voigt H, Classen R. Computer vision and digital imaging technology in melanoma detection. Semin. Oncol 29(4), 308–327 (2002).
   PubMedGoogle Scholar
• Andersen WK, Silvers DN. 'Melanoma? It can't be melanoma' A subset of melanomas that defies clinical recognition. JAMA 266(24), 3463–3465 (1991).
   PubMedGoogle Scholar
• Whited JD, Grichnik JM. The rational clinical examination. Does this patient have a mole or a melanoma?JAMA 279(9), 696–701 (1998).
   Google Scholar
• Grant-Kels JM, Bason ET, Grin CM. The misdiagnosis of malignant melanoma. J. Am. Acad. Dermatol 40(4), 539–548 (1999).
   Google Scholar
• Osborne JE, Bourke JF, Graham-Brown RA, Hutchinson PE. False-negative clinical diagnoses of malignant melanoma. BE J. Dermatol 140(5), 902–908 (1999).
   Google Scholar
• Bono A, Bartoli C, Moglia D eta]. Small melanomas: a clinical study on 270 consecutive cases of cutaneous melanoma. Melanoma Res. 9(6), 583–586 (1999).
   Google Scholar
• Bono A, Maurichi A, Moglia D eta]. Clinical and dermatoscopic diagnosis of early amelanotic melanoma. Melanoma Res. 11(5), 491–494 (2001).
   PubMedGoogle Scholar
• Argenziano G, Soyer HP, Chimenti S, Ruocco V. Impact of dermoscopy on the clinical management of pigmented skin lesions. Clin. Dermatol 20(3), 200–202 (2002).
   PubMedGoogle Scholar
• •Suggests dermoscopy may play a more important role in the management (lesion selection for biopsy) of suspicious skin lesions.
   Google Scholar
• Piepkorn M, Odland PB. Quality of care in the diagnosis of melanoma and related melanocytic lesions. Arch. Dermatol 133(11), 1393–1396 (1997).
   PubMedGoogle Scholar
• Calonje E. ACP best practice no 162. The histological reporting of melanoma. Association of Clinical Pathologists. J. Clin. Pathol 53(8), 587–590 (2000).
   Google Scholar
• McGinnis KS, Lessin SR, Elder DE etal Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. Arch. Dermatol 138(5), 617–621 (2002).
   PubMedGoogle Scholar
• ••Reviews primary melanocytic lesions,within the context of a multidisciplinary pigmented lesion clinic, resulted in changes in diagnosis in a significant proportion of cases that impacted on clinical decision making, patient outcome and research data collection. Supports the practice of pathology review at tertiary medical centers.
   Google Scholar
• Li LX, Crotty IKA, McCarthy SW Palmer AA, Kril JJ. A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions. Am. J Dermatopathol 22(6), 489–495 (2000).
   Google Scholar
• Bergman R, Malkin L, Sabo E, Kerner H. MIB-1 monoclonal antibody to determine proliferative activity of Ki-67 antigen as an adjunct to the histopathologic differential diagnosis of Spitz nevi. J. Am. Acad. Dermatol 44(3), 500–504 (2001).
   Google Scholar
• Bastian BC. Molecular cytogenetics as a diagnostic tool for typing melanocytic tumors. Recent Results. Cancer Res. 160, 92–99 (2002).
   PubMedGoogle Scholar
• Harvell JD, Bastian BC, LeBoit PE. Persistent (recurrent) Spitz nevi: a histopathologic, immunohistochemical and molecular pathologic study of 22 cases. Am. J. Sing. Pathol 26(5), 654–661 (2002).
   Google Scholar
• Bittner M, Meltzer P, Chen Y etal Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406 (6795), 536–40 (2000).
   PubMed Web of Science ®Google Scholar
• Ruiter DJ, van Muijen GN. Markers of melanocytic tumour progression. J. Pathol 186(4), 340–342 (1998).
   PubMedGoogle Scholar
• White WL. Immunomicroscopy in diagnostic dermatopathology: an update on cutaneous neoplasms. Adv. Dermatol 14, 359–396; discussion 397 (1999).
   Google Scholar
• Mangini J, Li N, Bhawan J. Immunohistochemical markers of melanocytic lesions: a review of their diagnostic usefulness. Am. J. Dermatopathol 24(3), 270–281 (2002).
   Google Scholar
• •Review of current and potential diagnostic markers of melanoma.
   Google Scholar
• Heintz PW, White CR Jr. Diagnosis: atypical fibroxanthoma or not? Evaluating spindle cell malignancies on sun damaged skin: a practical approach. Semin. Cutan. Med. Sing. 18(1), 78–83 (1999). too Kanik AB, Yaar M, Bhawan J. p75 nerve growth factor receptor staining helps identify desmoplastic and neurotropic melanoma.j Cutan. Pathol 23(3), 205–210 (1996). tot Orchard GE. Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma. Ifistochem. 32 (8), 475–481 (2000).
   Google Scholar
• Miettinen M, Fernandez M, Franssila K, Gatalica Z, Lasota J, Sarlomo-Rikala M. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am. J. Surg. Pathol 25(2), 205–211 (2001).
   Google Scholar
• Basarab T, Picard JK, Simpson E, Russell-Jones R. Melanoma antigen-encoding gene expression in melanocytic naevi and cutaneous malignant melanomas. BE J. Dermatol 140(1), 106–108 (1999).
   Google Scholar
• XU X, Chu AY, Pasha TL, Elder DE, Zhang PJ. Immunoprofile of MITF, tyrosinase, melan-A and MAGE-1 in HMB45-negative melanomas. Am. J. Surg. Pathol 26(1), 82–87 (2002).
   Google Scholar
• Boyle JL, Haupt HM, Stem JB, Multhaupt HA. Tyrosinase expression in malignant melanoma, desmoplastic melanoma and peripheral nerve tumors. Arch. Pathol Lab. Med. 126(7), 816–822 (2002).
   Google Scholar
• Huttenbach Y, Prieto VG, Reed JA. Desmoplastic and spindle cell melanomas express protein markers of the neural crest but not of later committed stages of Schwann cell differentiation. j Cutan. Pathol 29(9), 562–568 (2002).
   Google Scholar
• White WL, Hitchcock MG. Dying dogma: the pathological diagnosis of epidermotropic metastatic malignant melanoma. Semin. Diagn. Pathol 15 (3), 176–188 (1998).
   Google Scholar
• Zelger B, Sidoroff A. Antimetallothionein labeling. Am. J. Surg. Pathol 20(2), 253–257 (1996).
   Google Scholar
• Sugita K, Yamamoto 0, Asahi M. Immunohistochemical analysis of metallothionein expression in malignant melanoma in Japanese patients. Am. J. Dermatopathol 23(1), 29–35 (2001).
   Google Scholar
• Simonetti 0, Lucarini G, Brancorsini D et al Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2 and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer 95(9), 1963-1970 (2002).
   Google Scholar
• •Demonstrates that malignant melanocytic tumors displayed strong vascular endothelial growth factor (VEGF) expression while nevi do not, highlighting a potential role for VEGF in identifying melanomas whose histologic features overlap with melanocytic nevi.
   Google Scholar
• Bayer-Garner TB, Hough AJ Jr, Smoller BR. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness. Mod. Pathol 12(8), 770–774 (1999).
   Google Scholar
• Reed JA, Albino AR Update on diagnositic and prognositic markers in cutaneous malignant melanoma. Dermatol Clin. 17(3), 631–643 (1999).
   Google Scholar
• •Comprehensive review of molecular markers with emphasis on prognosis. iii Goding CR. Melanocyte development and malignant melanoma. Forum (Genova) 10(3), 176–187 (2000).
   Google Scholar
• Mu XC, Tran TA, Ross JS, Carlson JA. Topoisomerase II-a expression in melanocytic nevi and malignant melanoma. Cutan. Pathol 27(5), 242–248 (2000).
   PubMedGoogle Scholar
• Rieger E, Hofmann-Wellenhof R, Soyer HP etal Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. A quantitative immunohistochemical study. I Cutan. Pathol 20(3), 229–236 (1993).
   Google Scholar
• Sparrow LE, English DR, Taran JM, Heenan PJ. Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors. Am. Dermatopathol 20(1), 12–16 (1998).
   Google Scholar
• Fogt F, Vortmeyer AO, Tahan SR. Nucleolar organizer regions (AgNOR) and Ki-67 immunoreactivity in cutaneous melanocytic lesions. Am .1. Dermatopathol 17(1), 12–17 (1995).
   Google Scholar
• Kanoko M, Ueda M, Ichihashi M. PCNA expression and nucleolar organizer regions in malignant melanoma and nevus cell nevus. Kobej Med. Sc]. 40 (3–4), 107–123 (1994).
   Google Scholar
• Hussein MR, Roggero E, Sudilovsky EC, Tuthill RJ, Wood GS, Sudilovsky 0. Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi and cutaneous malignant melanomas. Am. J. Dermatopathol 23(4), 308–314 (2001).
   Google Scholar
• Ruiter DJ, Brocker EB. Immunohistochemistry in the evaluation of melanocytic tumors. Semin. Diagn. Pathol 10(1), 76–91 (1993).
   Google Scholar
• Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and darwinian selection in tumours. Trends Cell. Biol. 9(12), M57–60 (1999).
   Google Scholar
• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nature Rev Genet. 3(6), 415–428 (2002).
   Google Scholar
• Kirkham N. Optimal handling and criteria for melanoma diagnosis. HistoPathology 37(5), 467–469 (2000).
   PubMedGoogle Scholar
• McNutt NS, Urmacher C, Hakimian J, Hoss DM, Lugo J. Nevoid malignant melanoma: morphologic patterns and immunohistochemical reactivity. J. Cutan. Pathol 22(6), 502–517 (1995).
   Google Scholar
• Crotty IKA, Scolyer RA, Li L, Palmer AA, Wang L, McCarthy SW Spitz naevus versus Spitzoid melanoma: when and how can they be distinguished? Pathology34(1), 6–12 (2002).
   Google Scholar
• •Good review of the very difficult pathologic dilemma of differentiating a Spitz nevus (aka juvenile melanoma) from melanoma.
   Google Scholar
• Duncan LM, Deeds J, Cronin FE eta]. Melastatin expression and prognosis in cutaneous malignant melanoma. J. Clin. Oncol 19(2), 568–576 (2001).
   Google Scholar
• Deeds J, Cronin F, Duncan LM. Patterns of melastatin mRNA expression in melanocytic tumors. Hum. Pathol 31(11), 1346–1356 (2000).
   Google Scholar
• Maitra A, Gazdar AF, Moore TO, Moore AY. Loss of heterozygosity analysis of cutaneous melanoma and benign melanocytic nevi: laser capture microdissection demonstrates clonal genetic changes in acquired nevocellular nevi. Hum. Pathol 33(2), 191–197 (2002).
   PubMedGoogle Scholar
• Udart M, Utikal J, Krahn GM, Peter RU. Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia 3(3), 245–254 (2001).
   Google Scholar
• Korabiowska M, Brinck U, Kotthaus I, Berger H, Droese M. Analysis of the DNA content in the progression of recurrent and metastatic melanomas. Anticancer Res. 20(4), 2791–2794 (2000).
   PubMedGoogle Scholar
• Martin G, Halwani F, Shibata H, Meterissian S. Value of DNA ploidy and 5-phase fraction as prognostic factors in Stage III cutaneous melanoma. Can. J. Surg: 43(1), 29–34 (2000).
   Google Scholar
• Albertson DG, Ylstra B, Segraves R etal Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nature Genet. 25(2), 144–146 (2000).
   Google Scholar
• Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 58 (10), 2170–2175 (1998).
   PubMed Web of Science ®Google Scholar
• Bastian BC, Kashani-Sabet M, Hamm H et al Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res. 60(7), 1968–1973 (2000).
   Google Scholar
• •Reveals acral melanomas have unique chromosomal characteristics validating its histologic classification as a distinct entity with a disparate pathogenesis from conventional cutaneous melanoma and the histologically negative margins can still harbor residual tumors.
   Google Scholar
• Bastian BC, Wesselmann U, Pinkel D, Leboit PE. Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma. j Invest. Dermatol 113(6), 1065–1069 (1999).
   Google Scholar
• •Spitz nevi and melanoma can be differentiated at the chromosomal level.
   Google Scholar
• Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am. j Athol 157(3), 967–972 (2000).
   Google Scholar
• Bastian BC, Xiong J, Frieden IJ etal Genetic changes in neoplasms arising in congenital melanocytic nevi: differences between nodular proliferations and melanomas. Arn. Pathol 161(4), 1163–1169 (2002).
   PubMedGoogle Scholar
• •Demonstrates how comparative genomic hybridization could be used to as an aid to reliably diagnosis melanoma in cases where pathologic findings overlap between benign and malignant proliferations.
   Google Scholar
• Aitken JF, Elwood JM, Lowe JB, Firman DW, Balanda IQ, Ring IT A randomised trial of population screening for melanoma. j Med. Screen 9 (1), 33–37 (2002).
   Google Scholar
• ••Ongoing prospective study of thescreening for melanoma in Queensland, Australia. May reveal evidence for benefits of prevention of and screening for melanoma
   Google Scholar
• Evans RD, Kopf AW, Lew RA eta]. Risk factors for the development of malignant melanoma-I: review of case-control studies. Dermatol Sing. Oncol 14(4), 393–408 (1988).
   Google Scholar
• Weinstock MA, Colditz GA, Willett WC etal Melanoma and the sun: the effect of swimsuits and a 'healthy' tan on the risk of nonfamilial malignant melanoma in women. Am. Epidemiol 134 (5), 462–470 (1991).
   PubMedGoogle Scholar
• Bliss JM, Ford D, Swerdlow AJ etal Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int. .1. Cancer 62(4), 367–376 (1995).
   Google Scholar
• Sahin S, Levin L, Kopf AW etal Risk of melanoma in medium-sized congenital melanocytic nevi: a follow-up study. Am. Acad. Dermatol 39 (3), 428–33 (1998).
   Google Scholar
• Swerdlow AJ, English JS, Qiao Z. The risk of melanoma in patients with congenital nevi: a cohort study. j Am. Acad. Dermatol 32(4), 595–599 (1995).
   Google Scholar
• Rhodes AR, Melski JW. Small congenital nevocellular nevi and the risk of cutaneous melanoma. j Pecliatr 100(2), 219–224 (1982).
   Google Scholar
• Bittencourt FV, Marghoob AA, Kopf AW, Koenig KL, Bart RS. Large congenital melanocytic nevi and the risk for development of malignant melanoma and neurocutaneous melanocytosis. Pediatrics 106(4), 736–741 (2000).
   PubMedGoogle Scholar
• Rhodes AR, Weinstock MA, Fitzpatrick TB, Mihm CM Jr, Sober AJ. Risk factors for cutaneous melanoma: a practical method of recognizing predisposed individuals. JA/V/A 258(21), 3146–3154 (1987).
   Google Scholar
• Streutker CJ, McCready D, Jimbow K, From L. Malignant melanoma in a patient with oculocutaneous albinism. j Cutan. Med. Sing. 4(3), 149–152 (2000).
   Google Scholar
• Weinstock MA. Human models of melanoma. Clin. Dermatol 10(1), 83–89 (1992).
   PubMedGoogle Scholar
• Kraemer KH, Lee MM, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch. Dermatol 130(8), 1018–1021 (1994).
   Google Scholar
• Tucker MA, Boice JD Jr, Hoffman DA. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone and eye in Connecticut, 1935–82. Nail Cancer Inst. Monogr 68,161–189 (1985).
   Google Scholar
• Ford D, Bliss JM, Swerdlow AJ etal. Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE). Int. Cancer62(4), 377–381 (1995).
   Google Scholar
• Hemminki K, Lonnstedt I, Vaittinen P A population-based study of familial cutaneous melanoma. Melanoma Res. 11(2), 133–140 (2001).
   Google Scholar
• MacKie RM, McHenry P, Hole D. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high-risk groups. Lancet 341(8861), 1618–1620 (1993).
   PubMedGoogle Scholar
• Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int.j Cancer 73 (2), 198–203 (1997) .
   PubMed Web of Science ®Google Scholar
• •Good review of how sun exposure influences melanoma incidence.
   Google Scholar
• Green A, Bain C, McLennan R, Siskind V. Risk factors for cutaneous melanoma in Queensland. Recent Results Cancer Res. 102, 76–97 (1986).
   PubMedGoogle Scholar
• Milan T, Pukkala E, Verkasalo PK etal Subsequent primary cancers after basal-cell carcinoma: A nationwide study in Finland from 1953 to 1995. Int.j Cancer 87(2), 283–288 (2000).
   Google Scholar
• Efird J, Friedman G, Habel L, Tekawa I, Nelson L Risk of subsequent cancer following invasive or in situsquamous cell skin cancer. Ann 43iderniol. 12(7), 469 (2002).
   Google Scholar
• Stem RS. The risk of melanoma in association with long-term exposure to PUVA. jAm Acad. Dermatol 44(5), 755–761 (2001).
   Google Scholar
• Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br. Dermatol 143(3), 513–519 (2000).
   Google Scholar
• Jensen P, Hansen S, Moller B etal Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. jAm Acad. Dermatol 40(2 Pt 1), 177–186 (1999).
   Google Scholar
• Chen YT, Dubrow R, Zheng T, Barnhill RL, Fine J, Berwick M. Sunlamp use and the risk of cutaneous malignant melanoma: a population- based case-control study in Connecticut, USA. Int. j Epidemiol 27(5), 758–765 (1998).
   PubMedGoogle Scholar
• Swerdlow AJ, Weinstock MA. Do tanning lamps cause melanoma? An epidemiologic assessment. jAm. Acad. Dermatol 38 (1), 89–98 (1998).
   Google Scholar
• Austin DF, Reynolds P. Investigation of an excess of melanoma among employees of the Lawrence Livermore National Laboratory. Am. .1. Epidemiol 145(6), 524–531 (1997).
   Google Scholar
• Schallreuter KU, Levenig C, Berger J. Vitiligo and cutaneous melanoma. A case study. Dermatologica 183(4), 239–245 (1991).
   Google Scholar
• Bulliard JL, Cox B, Elwood JM. Latitude gradients in melanoma incidence and mortality in the non-Maori population of New Zealand. Cancer Causes Control5 (3), 234–240 (1994).
   PubMedGoogle Scholar
• Weinstock MA, Colditz GA, Willett WC et al Nonfamilial cutaneous melanoma incidence in women associated with sun exposure before 20 years of age. Pediatrics 84(2), 199–204 (1989).
   Google Scholar
• Mantelli M, Barile M, Ciotti P et al High prevalence of the G101W germline mutation in the CDKN2A (P166nk4aA gene in 62 Italian malignant melanoma families. Am.j Med. Genet. 107(3), 214–221 (2002).
   Google Scholar
• Auroy S, Avril ME, Chompret A eta]. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect. Genes Chromosomes Cancer 32(3), 195–202 (2001).
   Google Scholar
• Hashemi J, Platz A, Ueno T, Stierner U, Ringborg U, Hansson J. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res. 60(24), 6864–6867 (2000).
   Google Scholar
• Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in US melanoma-prone families with CDKN2A and CDK4 mutations. j Nail Cancer Inst. 92(12), 1006–1010 (2000).
   Google Scholar
• Tsao H, Zhang X, Kwitkiwski K, Finkelstein DM, Sober AJ, Haluska FG. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch. Dermatol 136(9), 1118–1122 (2000).
   Google Scholar
• Ruiz A, Puig S, Malvehy J, Lazar° C eta]. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other Neoplasia. j Med. Genet 36 (6), 490–493 (1999).
   Google Scholar
• Aitken J, Welch J, Duffy D etal CDKN2A variants in a population-based sample of Queensland families with melanoma. Nail Cancer Inst. 91(5), 446–452 (1999).
   Google Scholar
• Ghiorzo P, Ciotti P, Mantelli M eta]. Characterization of ligurian melanoma families and risk of occurrence of other Neoplasia. Int.j Cancer83(4), 441–448 (1999).
   Google Scholar
• MacKie RM, Andrew N, Lanyon WG, Connor JM. CDKN2A germline mutations in UK patients with familial melanoma and multiple primary melanomas. j Invest. Dermatol 111(2), 269–272 (1998).
   Google Scholar
• Monzon J, Liu L, Brill H eta]. CDKN2A mutations in multiple primary melanomas. NEtgIj Med 338(13), 879–887 (1998).
   Google Scholar
• Soufir N, Avril MF, Chompret A eta]. Prevalence of p 16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum. Mal Genet. 7(2), 209–216 (1998).
   Google Scholar
• Fargnoli MC, Chimenti S, Keller G eta]. CDKN2a/p16INK4a mutations and lack of p19ARF involvement in familial melanoma kindreds. j Invest. Dermatol 111(6), 1202–1206 (1998).
   Google Scholar
• Flores JF, Pollock PM, Walker GJ eta]. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene 15 (24), 2999–3005 (1997).
   Google Scholar
• Sun S, Pollock PM, Liu L eta]. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. int. Cancer 73 (4), 531–531 (1997) .
   Google Scholar
• Ciotti P, Strigini P, Bianchi-Scarra G. Familial melanoma and pancreatic cancer. Ligurian Skin Tumor Study Group. N Engl Med. 334(7), 469–470; discussion 471–472 (1996).
   Google Scholar
• FitzGerald MG, Harkin DP, Silva-Arrieta S etal Prevalence of germ-line mutations in p16, p19ARF and CDK4 in familial melanoma: analysis of a clinic-based population. Proc. Nail Acad. Sci. USA 93(16), 8541–8545 (1996).
   Google Scholar
• Borg A, Johannsson U, Johannsson 0 eta]. Novel germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res. 56(11), 2497–2500 (1996).
   Google Scholar
• Healy E, Sikkink S, Rees JL. Infrequent mutation of p16/A/K4in sporadic melanoma. Invest. Delmatol 107(3), 318–321 (1996).
   Google Scholar
• Liu L, I ncsam NJ, Slingerland JM eta]. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene11(2), 405–412 (1995).
   Google Scholar
• Walker GJ, Hussussian CJ, Flores JF eta]. Mutations of the CDKN2Ip1 6INK4 gene in Australian melanoma kindreds. Hum. Mol Genet. 4(10), 1845–1852 (1995).
   Google Scholar
• Gruis NA, van der Velden PA, Sandkuijl LA etal Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet. 10(3), 351–353 (1995).
   Google Scholar
• Hussussian CJ, Struewing JP, Goldstein AM etal Germline p16 mutations in familial melanoma. Nature Genet. 8(1), 15-21(1994).
   Google Scholar
• Kamb A, Shattuck-Eidens D, Eeles R etal Analysis of the p/6gene (CDKN4 as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet. 8(1), 23–26 (1994).
   Google Scholar
• Goldstein AM, Chidambaram A, Halpern A etal Rarity of CDK4germline mutations in familial melanoma. Melanoma Res. 12(1), 51–55 (2002).
   Google Scholar
• Kennedy C, ter Huurne J, Berkhout M eta]. Melanocortin-1 receptor (MC/1) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. .1. Invest. Dermatol 117(2), 294–300 (2001).
   Google Scholar
• Palmer JS, Duffy DL, Box NF etal Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am. j Hum. Genet. 66 (1), 176–186 (2000).
   Google Scholar
• Ichii-Jones F, Lear JT, Heagerty AH etal. Susceptibility to melanoma: influence of skin type and polymorphism in the melanocyte stimulating hormone receptor gene. .1. Invest. Dermatol 111(2), 218–221 (1998).
   Google Scholar
• Valverde P, Healy E, Sikkink S etal The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum. Mal Genet. 5(10), 1663–1666 (1996).
   Google Scholar
• Piccolo D, Chimenti S. Dermoscopic diagnosis by a trained clinician versus a clinician with minimal dermoscopy training versus computer-aided diagnosis of 341 pigmented skin lesions: a comparative study. Br. Dermatol 147(3), 481–486 (2002).
   Google Scholar
• •Demonstrates that either a trained dermatologist or automated diagnosis system can improve the diagnostic accuracy of melanoma compared to an inexperienced clinician. Suggest that computer diagnosis might be a useful for the screening of melanoma in centers not experienced in derrnoscopy.
   Google Scholar
• Moncrieff M, Cotton S, Claridge E, Hall P. Spectrophotometric intracutaneous analysis: a new technique for imaging pigmented skin lesions. BE j Dermatol 146(3), 448–457 (2002).
   PubMed Web of Science ®Google Scholar
• Busam KJ, Charles C, Lee G, Halpern AC. Morphologic features of melanocytes, pigmented keratinocytes and melanophages by in vivo confocal scanning laser microscopy. Mod. Pallid 14(9), 862–868 (2001).
   Google Scholar
• Zembowicz A, McCusker M, Chiarelli C eta]. Morphological analysis of nevoid melanoma: a study of 20 cases with a review of the literature. Am. J. Dermatopathol 23(3), 167–175 (2001).
   Google Scholar
• Quinn MJ, Crotty IKA, Thompson JF, Coates AS, O'Brien CJ, McCarthy WH. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer83(6), 1128–1135 (1998).
   Google Scholar
• Li LX, Crotty KA, Palmer AA eta]. Differentiating benign nevi from malignant melanoma using DNA microdensitometry and karyometry and maturation: a zonal comparison, correlation and multivariate analysis. Anal Quant. GYM]: Pistol. 24(4), 234–243 (2002).
   Google Scholar
• •Demonstrates that cytometric analysis can accurately diagnosis melanoma (98% efficiency).
   Google Scholar
• Tran TA, Ross JS, Carlson JA, Mihm MC Jr. Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions. Hum. Pallid 29(10), 1085–1090 (1998).
   Google Scholar
• Georgieva J, Sinha P, Schadendorf D. Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. j Gun. Athol 54(3), 229–235 (2001).
   Google Scholar
• Florenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Gun. Cancer Res. 6(9), 3614–3620 (2000).
   Google Scholar
• Flores JF, Walker GJ, Glendening JM et al Loss of the pl6INK4a and pl5INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res. 56(21), 5023–5032 (1996).
   Google Scholar
• Wagner SN, Wagner C, Briedigkeit L, Goos M. Homozygous deletion of the pl6INK4a and the pl5INK4b tumour suppressor genes in a subset of human sporadic cutaneous malignant melanoma. Br. Dermatol 138(1), 13–21 (1998).
   Google Scholar
• Sparrow LE, Eldon MJ, English DR, Heenan PJ. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am. Dermatopathol 20(3), 255–261 (1998).
   Google Scholar
• Trotter MJ, Tang L, Tron VA. Overexpression of the cyclin-dependent kinase inhibitor p21(VVAF1/CIP1) in human cutaneous malignant melanoma. Cutan. Pallid 24(5), 265–271 (1997).
   Google Scholar
• Florenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R. Protein expression of the cell-cycle inhibitor p271Kipl in malignant melanoma: inverse correlation with disease-free survival. Am. Pallid 153(1), 305–312 (1998).
   Google Scholar
• Gelsleichter L, Gown AM, Zarbo RJ, Wang E, Coltrera MD. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2 and markers of cell proliferation in primary versus metastatic tumors. Mod Athol 8(5), 530–535 (1995).
   Google Scholar
• Korabiowska M, Brinck U, Hoenig JF eta]. Significance of p53antigen in malignant melanomas and nevi of the head and neck area. Anticancer Res. 15(3), 885–889 (1995).
   Google Scholar
• Korabiowska M, Betke H, Kellner S, Stachura J, Schauer A. Differential expression of growth arrest, DNA damage genes and tumour suppressor gene p53 in nevi and malignant melanomas. Anticancer Res. 17(5A), 3697–3700 (1997).
   Google Scholar
• Bodey B, Kaiser HE, Goldfarb RII. Immunophenotypically varied cell subpopulations in primary and metastatic human melanomas. Monoclonal antibodies for diagnosis, detection of neoplastic progression and receptor directed immunotherapy. Anticancer Res. 16(1), 517–531 (1996).
   Google Scholar
• Korabiowska M, Brinck U, Ruschenburg I, Schlott T, Droese M, Stachura J. Bc12 and Bax expression in nevi and melanomas and their relation to ploidy status and proliferation. Pol. j Pallid 50(1), 17–21 (1999).
   Google Scholar
• Dome B, Somlai B, Timar J. The loss of NM23 protein in malignant melanoma predicts lymphatic spread without affecting survival. Anticancer Res. 20(5C), 3971–3974 (2000).
   Google Scholar
• Shukuwa T, Katayama I, Koji T Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas. Mod. Pallid 15(4), 387–396 (2002).
   Google Scholar
• Miracco C, Santopietro R, Biagioli M etal Different patterns of cell proliferation and death and oncogene expression in cutaneous malignant melanoma. j Cutan. Athol 25(5), 244–251 (1998).
   Google Scholar
• Kraehn GM, Utikal J, Udart M eta]. Extra c-myc Oncogene copies in high-risk cutaneous malignant melanoma and melanoma metastases. BE j Cancer 84(1), 72–79 (2001).
   Google Scholar
• Luca MR, Bar-Eli M. Molecular changes in human melanoma metastasis. Hstol. Hstopathol 13(4), 1225–1231 (1998).
   PubMedGoogle Scholar
• Whiteman DC, Zhou XP, Cummings MC, Pavey S, Hayward NK, Eng C. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. int. Cancer 99(1), 63–67 (2002).
   PubMedGoogle Scholar
• Poetsch M, Dittberner T, Woenckhaus C. PTEN/MMAC1 in malignant melanoma and its importance for tumor progression. Cancer Genet. Cytogenet. 125(1), 21–26 (2001).
   Google Scholar
• Celebi JT, Shendrik I, Silvers DN, Peacocke M. Identification of PTEN mutations in metastatic melanoma specimens. J. Med. Genet. 37 (9), 653–657 (2000).
   Google Scholar
• Santa Cruz DJ, Hamilton PD, Klos DJ, Fernandez-Pol JA. Differential expression of metallopanstimulin/S27 ribosomal protein in melanocytic lesions of the skin. J. Cutan. Radial 24(9), 533–542 (1997).
   Google Scholar
• Shirasaki F, Takata M, Hatta N, Takehara K. Loss of expression of the metastasis suppressor gene KiSS1 during melanoma progression and its association with LOH of chromosome 6q16.3—q23. Cancer Res. 61(20), 7422–7425 (2001).
   Google Scholar
• Miracco C, Pacenti L, Santopietro R, Laurini L, Biagioli M, Luzi P Evaluation of telomerase activity in cutaneous melanocytic proliferations. Hum. Pallid 31(9), 1018–1021 (2000).
   Google Scholar
• Meije CB, Das PK, Jans MM et al. Multiple complementary transcripts of pCMal, a novel gene located at chromosome 11p15.1-2 and melanocytic cell transformation. Pathol 197(5), 668–676 (2002).
   Google Scholar
• Korabiowska M, Brinck U, Dengler H, Stachura J, Schauer A, Droese M. Analysis of the DNA mismatch repair proteins expression in malignant melanomas. Anticancer Res. 20(6B), 4499–4505 (2000).
   Google Scholar
• Sparrow LE, Heenan PJ. Differential expression of epidermal growth factor receptor in melanocytic tumours demonstrated by immunohistochemistry and mRNA in situ hybridization. Australas.j Dermatol. 40(1), 19–24 (1999).
   Google Scholar
• Ohashi A, Funasaka Y, Ueda M, Ichihashi M. c-KIT receptor expression in cutaneous malignant melanoma and benign melanotic naevi. Melanoma Res. 6(1), 25–30 (1996).
   Google Scholar
• Eliopoulos P, Mohammed MQ, Henry K, Retsas S. Overexpression of HER-2 in thick melanoma. Melanoma Res. 12 (2), 139–145 (2002).
   Google Scholar
• Korabiowska M, Mirecka J, Brinck U, Hoefer K, Marx D, Schauer A. Differential expression of cerbB3 in nevi and malignant melanomas. AntiCancer Res. 16(1), 471–474 (1996).
   Google Scholar
• Natali PG, Hamby CV, Felding- Habermann B et al Clinical significance of a(v)03 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res. 57(8), 1554–1560 (1997).
   Google Scholar
• Van Belle PA, Elenitsas R, Satyamoorthy K, Wolfe JT, Guerry Dt, Schuchter L et al Progression-related expression of beta3 integrin in melanomas and nevi. Hum. Pathol. 30(5), 562–567 (1999).
   Google Scholar
• Nesbit M, Herlyn M. Adhesion receptors in human melanoma progression. Invasion Metastasis 14 (1-6), 131–146 (1994).
   PubMedGoogle Scholar
• Demunter A, Libbrecht L, Degreef H, De Wolf-Peeters C, van den Oord JJ. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations. Mod. Pathol. 15(4), 454–461 (2002).
   Google Scholar
• Schaider H, Soyer HP, Heider KH etal CD44 and variants in melanocytic skin neoplasms. j Cutan. Athol 25 (4), 199–203 (1998).
   Google Scholar
• Harwood CA, Green MA, Cook MG. CD44 expression in melanocytic lesions: a marker of malignant progression? BE Dermatol 135(6), 876–882 (1996).
   Google Scholar
• van Duinen CM, van den Broek LJ, Vermeer BJ, Fleuren GJ, Bruijn JA. The distribution of cellular adhesion molecules in pigmented skin lesions. Cancer 73(8), 2131–2139 (1994).
   PubMedGoogle Scholar
• Denton KJ, Stretch JR, Gaiter KC, Harris AL. A study of adhesion molecules as markers of progression in malignant melanoma. Pathol 167(2), 187–191 (1992).
   Google Scholar
• Silye R, Karayiannakis AJ, Syrigos KN etal E-cadherin/catenin complex in benign and malignant melanocytic lesions. j Pallid 186(4), 350–355 (1998).
   Google Scholar
• Goncharuk VN, Ross JS, Carlson JA. Actin-binding protein fascin expression in skin Neoplasia. .1. Cutan. Pallid 29(7), 430–438 (2002).
   Google Scholar
• Shih IM, Elder DE, Hsu MY, Herlyn M. Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am j Athol 145(4), 837–845 (1994).
   Google Scholar
• Moretti S, Pinzi C, Spallanzani A eta]. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int. j Cancer 84(2), 160–168 (1999).
   Google Scholar
• •Demonstrates that melanoma cells utilize cascades of growth factors and cytokines in the progression from nevi to metastasis.
   Google Scholar
• Busam KJ, Iversen K, Berwick M, Spagnoli GC, Old LJ, Jungbluth AA. Immunoreactivity with the antiMAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters. Mod. Athol 13(4), 459–465 (2000).
   Google Scholar
• Van den Oord JJ. Expression of CD26/ dipeptidyl-peptidase IV in benign and malignant pigment-cell lesions of the skin. Br. Detmatol 138(4), 615–621 (1998).
   Google Scholar
• Reed JA, McNutt NS, Prieto VG, Albino AR Expression of transforming growth factor-0 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am. Pallid 145(1), 97–104 (1994).
   Google Scholar
• Reed JA, McNutt NS, Albino AP. Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression. Am. j Pallid 144(2), 329–336 (1994).
   Google Scholar
• al-Alousi S, Carlson JA, Blessing K, Cook M, Karaoli T, Barnhill RL. Expression of basic fibroblast growth factor in desmoplastic melanoma. j Cutan. Athol 23(2), 118–125 (1996).
   Google Scholar
• Halaban R, Kwon BS, Ghosh S, Delli Bovi P, Baird A. bFGF as an autocrine growth factor for human melanomas. Oncogene Res. 3(2), 177–186 (1988).
   PubMedGoogle Scholar
• Delbaldo C, Masouye I, Saurat JH, Vassalli JD, Sappino AR Plasminogen activation in melanocytic Neoplasia. Cancer Res. 54(16), 4547–4552 (1994).
   Google Scholar
• de Vries TJ, Quax PH, Denijn M eta]. Plasminogen activators, their inhibitors and urokinase receptor emerge in late stages of melanocytic tumor progression. Am. Pathol 144(1), 70–81 (1994).
   Google Scholar
• Frohlich E, Schlagenhauff B, Mohrle M, Weber E, Klessen C, Rassner G. Activity, expression and transcription rate of the cathepsins B, D, H and L in cutaneous malignant melanoma. Cancer 91 (5), 972–982 (2001).
   PubMedGoogle Scholar
• Bogdan I, Xin H, Burg G, Boni R. Heterogeneity of allelic deletions within melanoma metastases. Melanoma Res. 11(4), 349–354 (2001).
   Google Scholar
• Healy E, Belgaid CE, Takata M eta]. Allelotypes of primary cutaneous melanoma and benign melanocytic nevi. Cancer Res. 56(3), 589–593 (1996).
   PubMedGoogle Scholar
• Indsto JO, Cachia AR, Kefford RF, Mann GJ. X inactivation, DNA deletion and microsatellite instability in common acquired melanocytic nevi. Clin. Cancer Res. 7(12), 4054–4059 (2001).
   PubMedGoogle Scholar
• •Melanocytic nevi are clonal but do not share common chromosomal aberrations.
   Google Scholar
• Lee JD, Unger ER, Gittenger C, Lee DR, Hebert R, Maize JC. Interphase cytogenetic analysis of 1q12 satellite III DNA in melanocytic lesions: increased aneuploidy with malignant histology. Am. Dermatopathol 23(3), 176–180 (2001).
   Google Scholar
• Balaban GB, Herlyn M, Clark WH Jr, Nowell PC. Karyotypic evolution in human malignant melanoma. Cancer Genet. Cytogenet. 19(1-2), 113–122 (1986).
   Google Scholar
• Umebayashi Y, Otsuka E DNA-ploidy abnormalities are a reflection of the metastatic potential of malignant melanoma. Microfluorometric DNA analysis. Acta Derm. Venemol 77(2), 118–121 (1997).
   Google Scholar
• Schmidt B, Weinberg DS, Hollister K, Barnhill RL. Analysis of melanocytic lesions by DNA image cytometry. Cancer 73(12), 2971–2977 (1994).
   PubMedGoogle Scholar
• Karlsson M, Boeryd B, Carstensen J, Kagedal B, Wingren S. DNA ploidy and 5-phase fraction in primary melanomas and their regional metastases. Melanoma Res. 4(1), 47–51 (1994).
   Google Scholar